CRISPR Therapeutics is a leading biotechnology company pioneering the development of gene-editing therapies to treat a wide range of serious diseases. Their innovative approach utilizes the CRISPR/Cas9 platform to create precise, efficient, and versatile treatments. In collaboration with Vertex Pharmaceuticals, they developed CASGEVY™ (exagamglogene autotemcel), the first-ever approved CRISPR-based therapy for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. With a diverse pipeline, CRISPR Therapeutics is advancing programs in hemoglobinopathies, immuno-oncology, autoimmune diseases, in vivo editing, and regenerative medicine, aiming to transform patient care globally.